CD8A and neoplasm: Concurrent anti-PD-L1 antibody administration activated CD8 T Cells markedly and increased CD8 and NK cell-mediated systemic antitumor immunity, which resulted in superior systemic antitumor immune responses and distant tumor growth suppression.